The Next Generation of Weight Loss Research Is Here
While most people are still researching first-generation GLP-1 compounds, a triple receptor agonist called Retatrutide has already produced Phase 2 data that makes everything before it look incremental. This is what serious researchers are looking at now.
Third-party lab tested · COA documentation included · Sourced from Werner Science.
Get Retatrutide at Werner Science →Use code SAVE10 at checkout for 10% off.
Why Triple Receptor Agonism Works Differently
First-generation research focused on a single pathway: GLP-1 receptor activation. That was a meaningful step. Then dual agonists added GIP receptor targeting, improving results further. Retatrutide adds a third: glucagon receptor activation.
The glucagon receptor component is what separates Retatrutide from everything before it. Where GLP-1 suppresses appetite and GIP modulates insulin and lipid metabolism, glucagon receptor activation directly increases energy expenditure. The body burns more, not just takes in less.
Phase 2 data showed up to 24% total body weight reduction over 48 weeks, a number that would have seemed implausible from a non-surgical intervention five years ago.
The Lead Research Compound
Retatrutide is the centerpiece of next-generation metabolic research, available at Werner Science with batch-specific COA documentation.
The centerpiece of next-generation metabolic research. Activates GLP-1, GIP, and glucagon receptors simultaneously, producing results no single or dual receptor compound has matched in published data. Phase 2 trials showed up to 24% body weight reduction over 48 weeks at the highest dose range studied.
Source Retatrutide at Werner Science →Retatrutide's Phase 2 results represent the highest published body weight reduction of any peptide compound to date. Werner Science carries the full catalog for researchers who want to explore what comes next.
View Research Compounds →Why Researchers Are Moving to Retatrutide
The progression from single to dual to triple receptor agonists wasn't random. Each step asked the same question: what else is the body capable of when you give it the right signals?
GLP-1 activation established the foundation. Reduce appetite, improve glucose handling, slow gastric emptying. That worked. But it left significant metabolic levers untouched. Adding GIP receptor activation was the first meaningful leap, targeting lipid metabolism and fat storage. Researchers began seeing not just reduced intake but improved partitioning: more fat oxidized, less stored, less muscle loss.
Retatrutide adds the glucagon receptor. In the metabolic research context, glucagon receptor activation increases energy expenditure directly. The body burns more at rest. Reduced intake, improved fat utilization, and increased expenditure combined to produce Phase 2 figures that caught the research community's attention: up to 24% body weight reduction over 48 weeks. No prior compound had reached that without surgical intervention.
That ceiling has moved. Retatrutide is the clearest signal yet of how far.
How Serious Researchers Source Retatrutide
Not all peptide research is conducted the same way. Researchers who get meaningful data from Retatrutide protocols typically focus on a few fundamentals:
- ✓Sourcing compounds with verified purity and third-party COA documentation
- ✓Maintaining detailed logs of dosing, timing, and observable outcomes
- ✓Supporting protocols with appropriate nutritional frameworks to preserve lean mass
- ✓Working from batch-specific documentation, not generic supplier claims
Retatrutide, GLOW, and SEMTEX are available with third-party COA documentation at Werner Science.
View the Full Peptide Catalog →Ready to Explore the Research?
Retatrutide is available at Werner Science with batch-specific COA documentation and HPLC purity verification.
Shop Werner Science →Use code SAVE10 at checkout for 10% off.